착상전 유전학적 검사 시장 : 제품별, 주기별, 기술별, 시술별, 용도별, 최종 사용자별, 지역별(2024-2031년)

Preimplantation Genetic Testing Market Valuation - 2024-2031

The growing awareness and use of assisted reproductive technologies (ART), along with increased occurrences of genetic abnormalities and infertility concerns, is propelling the preimplantation genetic testing (PGT) market. According to the analyst from Verified Market Research, the Preimplantation Genetic Testing Market is estimated to reach a valuation of USD 1334.09 Million in 2031 over the forecast subjugating around USD 621.91 Million valued in 2023.

Advancements in genomic technologies, such as next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH), are allowing for more precise and comprehensive genetic screening, accelerating market growth. It enables the market to grow at a CAGR of 10.01% from 2024 to 2031.

Preimplantation Genetic Testing Market: Definition/Overview

Preimplantation Genetic Testing (PGT) is a specialized genetic testing process for embryos generated through in vitro fertilization (IVF). Before being put into the uterus, one or a few cells from each embryo are biopsied to determine their genetic makeup. PGT is primarily used to discover genetic abnormalities, chromosomal problems, or specific genetic mutations in embryos, allowing prospective parents to make educated decisions about embryo selection for implantation.

Furthermore, this method is especially useful for couples at risk of passing on genetic illnesses, individuals with a history of recurrent pregnancy loss or unsuccessful IVF attempts, and older women seeking fertility treatments. PGT allows for the selection of embryos free of genetic diseases, boosting the chances of a successful pregnancy and the birth of a healthy child.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Influencing the Growth of the Preimplantation Genetic Testing Market?

Genetic testing is gaining popularity among the general public, owing to a better understanding of its benefits in detecting genetic abnormalities and ailments early in the embryonic stage. This awareness is accompanied by a rising preference for healthy babies, particularly among couples with a history of genetic diseases, those of advanced maternal age, or those who have experienced several pregnancy losses. This desire to protect future generations' health and well-being is an important driver to establishing preimplantation genetic testing (PGT).

The Preimplantation Genetic Testing Market has profited greatly from advances in genetic testing technologies such as Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Microarray methods. These technologies have increased the accuracy, efficiency, and speed of genetic testing, making PGT more accessible and dependable. Furthermore, advances in IVF equipment and procedures support these genetic testing improvements, making it easier to incorporate PGT into fertility treatments.

Furthermore, the global prevalence of genetic illnesses is increasing, owing in part to improved diagnosis procedures and more awareness. Couples with known genetic problems in their families, as well as those who have had unexplained infertility, miscarriages, or stillbirths, are more likely to choose PGT to lower the possibility of transferring genetic abnormalities to their children. This generational trend broadens the potential consumer base for PGT services, resulting in market growth.

Will Ethical Concerns Restrain Adoption of Preimplantation Genetic Testing?

Preimplantation genetic testing (PGT) is the process of evaluating embryos for genetic problems before to pregnancy using in vitro fertilization. This raises ethical concerns about selecting embryos based on genetic features, which might lead to "designer babies." There is a narrow line between utilizing PGT to avoid major genetic illnesses and choosing desirable features, which creates social, moral, and ethical concerns about eugenics, injustice, and prejudice, thereby limiting market growth.

While PGT technologies have made tremendous advances, they still have limits in terms of accuracy, efficiency, and capacity to detect a wide spectrum of genetic disorders. False positives or negatives occur, resulting in the destruction of viable embryos or the selection of embryos with undiagnosed genetic abnormalities. Improving the accuracy and scope of PGT necessitates continual research and development, which is expensive and time-consuming, limiting market expansion.

Category-wise Acumens

How does the Dominance of the Reagents and Consumables Impact the Market?

According to VMR analyst, the reagents and consumables segment is anticipated to dominate the segment within the Preimplantation Genetic Testing Market. Reagents and consumables are required at all stages of the PGT process, from DNA amplification to analysis. These items are used in big quantities and require regular replenishment, resulting in a steady demand. Unlike instruments, which are long-term capital investments, reagents and consumables are continuing operating expenses for genetic testing laboratories. This large volume utilization greatly increases their market share.

The field of genetic testing, including PGT, is quickly growing, with ongoing advances and breakthroughs in reagents and consumables. These advancements have the potential to improve the accuracy, speed, and efficiency of testing processes. Also, the flexibility to tailor reagents and consumables to specific tests or conditions helps accelerate their adoption, addressing the precise requirements of PGT laboratories and clinics.

Furthermore, reagents and consumables are used in a variety of PGT procedures, including Preimplantation Genetic Screening (PGS) for aneuploidy detection, Preimplantation Genetic Diagnosis (PGD) for single gene diseases, and newer approaches for structural rearrangements and mitochondrial illnesses. These products' market domination is due to their adaptability and requirement in a variety of PGT applications.

How does the Rising Awareness of Genetic Disorders Contribute to the PGD Segment?

The preimplantation genetic diagnosis (PGD) segment is estimated to hold the largest share of the Preimplantation Genetic Testing Market during the forecast period. PGD is utilized specifically by couples who are known to have a high chance of passing on specific genetic disorders to their children. This specialized approach to testing detects single-gene disorders and chromosomal anomalies unique to the parents' genetic origins, making it an essential tool for families looking to avoid the transfer of hereditary diseases. The need for PGD stems from its capacity to bring peace of mind to at-risk couples by ensuring the birth of healthy offspring free of specific genetic abnormalities.

Furthermore, the general public and healthcare professionals are becoming increasingly aware of the benefits of genetic testing in preventing inherited disorders. This awareness, combined with the rising occurrence of genetic abnormalities due to a variety of reasons, including longer parental ages at conception, has resulted in increased demand for PGD. Prospective parents are becoming more knowledgeable and proactive about their reproductive options, resulting in an increase in the use of PGD to assure the health and well-being of their future offspring.

Country/Region-wise Acumens

How will Demand for Preimplantation Genetic Testing Shape the North American Market?

According to VMR analysis, the North American region is estimated to dominate in Preimplantation Genetic Testing Market during the forecast period. Genetic testing and its benefits are widely understood and accepted in North America. This is due in part to healthcare providers' educational efforts, patient group activism, and media and popular culture coverage. As a result, there is a high demand for genetic testing services, including PGT, among people and couples seeking to uncover genetic abnormalities, assess risks to future children, and make educated reproductive decisions. This desire is amplified by the cultural acceptance of IVF and related reproductive technologies.

Furthermore, North America, particularly the United States, has some of the world's most advanced healthcare infrastructure, with cutting-edge medical facilities, leading-edge research institutions, and a strong emphasis on new healthcare solutions. This infrastructure facilitates considerable research and development efforts in genetic testing and reproductive technologies. Furthermore, substantial healthcare expenditure in the region, both public and private, allows for significant investment in new technology and treatments, making modern PGT services broadly available to patients.

Will the Asia Pacific prove Opportunistic for the Preimplantation Genetic Testing Market?

Asia Pacific is estimated to grow at the highest CAGR in the Preimplantation Genetic Testing Market. This region has experienced substantial growth in awareness and acceptance of genetic testing and its potential advantages. This is attributable to improved knowledge, more access to information via digital platforms, and government-led initiatives to promote genetic health. As a result, more people and couples are using PGT as part of their family planning, increasing market demand.

Furthermore, governments around Asia Pacific are making significant investments in healthcare infrastructure as well as encouraging biotechnology and genetic engineering research. Countries such as China, Japan, South Korea, and Singapore are setting the standard for enacting policies that encourage the adoption of modern medical technology, including PGT. These measures, combined with supporting legislative frameworks, are considerably boosting the region's PGT market.

Competitive Landscape

The competitive landscape of the preimplantation genetic testing (PGT) market is marked by a constant interplay of technology breakthroughs, regulatory frameworks, and shifting customer preferences. Furthermore, cooperation among healthcare providers, research institutions, and technology companies are pushing innovation and broadening the use of PGT beyond typical genetic disorders to include broader genomic profiling.

Some of the prominent players operating in the Preimplantation Genetic Testing Market include:

Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis, Igenomix.

Latest Developments:

In April 2023, Eurofins Genoma, a leader in the PGT market, launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. This new test analyses cell-free foetal DNA in the maternal bloodstream, providing a less intrusive option for couples undergoing in vitro fertilization (IVF).

In April 2023, LifeView, powered by Genomic Prediction, announced a partnership with Ovation Fertility. This agreement gives Ovation patients access to the LifeView PGT Platform, which provides cutting-edge technology and might significantly improve their clinical care experience.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PREIMPLANTATION GENETIC TESTING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Reagents and Consumables
• 5.3 Instruments
• 5.4 Software and Services

6 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY CYCLE TYPE

• 6.1 Overview
• 6.2 Fresh Non-donor
• 6.3 Frozen Non-donor
• 6.4 Fresh Donor
• 6.5 Frozen Donor

7 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

• 7.1 Overview
• 7.2 Next-generation Sequencing (NGS)
• 7.3 Polymerase Chain Reaction (PCR)
• 7.4 Fluorescence In Situ Hybridization
• 7.5 Comparative Genomic Hybridization
• 7.6 Single-nucleotide Polymorphism

8 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE

• 8.1 Overview
• 8.2 Preimplantation Genetic Screening
• 8.3 Preimplantation Genetic Diagnosis

9 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

• 9.1 Overview
• 9.2 Aneuploidy
• 9.3 Structural Chromosomal Abnormalities
• 9.4 Single Gene Disorders
• 9.5 X-linked Disorders
• 9.6 HLA Typing
• 9.7 Gender Identification

10 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY END-USER

• 10.1 Overview
• 10.2 Fertility Clinics
• 10.3 Hospitals
• 10.4 Diagnostic Laboratories
• 10.5 Other End Users

11 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY GEOGRAPHY

• 11.1 Overview
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 U.K.
  • 11.3.3 France
  • 11.3.4 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Rest of Asia Pacific
• 11.5 Rest of the World
  • 11.5.1 Latin America
  • 11.5.2 Middle East and Africa

12 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET COMPETITIVE LANDSCAPE

• 12.1 Overview
• 12.2 Company Market Share
• 12.3 Vendor Landscape
• 12.4 Key Development Strategies

13 COMPANY PROFILES

• 13.1 Illumina, Inc.
  • 13.1.1 Overview
  • 13.1.2 Financial Performance
  • 13.1.3 Product Outlook
  • 13.1.4 Key Developments
• 13.2 Thermo Fisher Scientific Inc.
  • 13.2.1 Overview
  • 13.2.2 Financial Performance
  • 13.2.3 Product Outlook
  • 13.2.4 Key Developments
• 13.3 Agilent Technologies, Inc.
  • 13.3.1 Overview
  • 13.3.2 Financial Performance
  • 13.3.3 Product Outlook
  • 13.3.4 Key Developments
• 13.4 Perkinelmer, Inc.
  • 13.4.1 Overview
  • 13.4.2 Financial Performance
  • 13.4.3 Product Outlook
  • 13.4.4 Key Developments
• 13.5 Coopersurgical, Inc.
  • 13.5.1 Overview
  • 13.5.2 Financial Performance
  • 13.5.3 Product Outlook
  • 13.5.4 Key Developments
• 13.6 Abbott Laboratories
  • 13.6.1 Overview
  • 13.6.2 Financial Performance
  • 13.6.3 Product Outlook
  • 13.6.4 Key Developments
• 13.7 Natera, Inc.
  • 13.7.1 Overview
  • 13.7.2 Financial Performance
  • 13.7.3 Product Outlook
  • 13.7.4 Key Developments
• 13.8 Rubicon Genomics
  • 13.8.1 Overview
  • 13.8.2 Financial Performance
  • 13.8.3 Product Outlook
  • 13.8.4 Key Developments
• 13.9 Oxford Gene Technology
  • 13.9.1 Overview
  • 13.9.2 Financial Performance
  • 13.9.3 Product Outlook
  • 13.9.4 Key Developments
• 13.10 Yikon Genomics
  • 13.10.1 Overview
  • 13.10.2 Financial Performance
  • 13.10.3 Product Outlook
  • 13.10.4 Key Developments
• 13.11 Scigene
  • 13.11.1 Overview
  • 13.11.2 Financial Performance
  • 13.11.3 Product Outlook
  • 13.11.4 Key Developments
• 13.12 Beijing Genomics Institute
  • 13.12.1 Overview
  • 13.12.2 Financial Performance
  • 13.12.3 Product Outlook
  • 13.12.4 Key Developments
• 13.13 Good Start Genetics
  • 13.13.1 Overview
  • 13.13.2 Financial Performance
  • 13.13.3 Product Outlook
  • 13.13.4 Key Developments
• 13.14 Invicta Genetics
  • 13.14.1 Overview
  • 13.14.2 Financial Performance
  • 13.14.3 Product Outlook
  • 13.14.4 Key Developments
• 13.15 Combimatrix
  • 13.15.1 Overview
  • 13.15.2 Financial Performance
  • 13.15.3 Product Outlook
  • 13.15.4 Key Developments
• 13.16 Genea Limited
  • 13.16.1 Overview
  • 13.16.2 Financial Performance
  • 13.16.3 Product Outlook
  • 13.16.4 Key Developments
• 13.17 Progenesis
  • 13.17.1 Overview
  • 13.17.2 Financial Performance
  • 13.17.3 Product Outlook
  • 13.17.4 Key Developments

14 Appendix

• 14.1 Related Reports